Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $4.7M rose 43.5% year over year, behind the +52.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 43.4% from the prior quarter. Over 3 fiscal years it compounded at +62.5% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +56.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.7M-43.4% QoQ
Last fiscal yearDec 2025
$17.1M+56.7% YoY
LTMMar 2026
$17.83M+52.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.5%-100.0%-143.5 pp
1 year+56.7%-100.0%-156.7 pp
3-year CAGR+62.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

Mixed currencies · from the income statement

Latest · FY2025
17.1M USD
Year-over-year change
+56.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +52.6% is the 3rd highest of 9, against a peer median of +18.3%.
  • Over three fiscal years its annual growth of +62.5% compares with a peer median of +10.0%.
EPRX Competitors
Selling, General & Admin for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$30.27M USD+4.4%+9.7%1705.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M USD+11.1%+24.6%82.5%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$23.69M USD+2.7%+2.7%—
TARAProtara Therapeutics, Inc.LTM Mar 2026$23.01M USD+25.6%+1.9%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$20.02M USD———
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$17.83M USD+52.6%+62.5%—
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$16.97M USD+137.1%+72.2%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$16.29M USD+45.3%-0.9%—
MDWDMediWound Ltd.LTM Mar 2026$14.41M USD+9.9%+10.3%99.5%
Peer median (excluding EPRX) —+18.3%+10.0%650.8%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue112.38K00163.47K331.89K
Gross Profit(112.38K)00(163.47K)(331.89K)
Gross Margin—————
Research & Development7.59M13.63M15.33M16.07M29.51M
Selling, General & Admin6.97M3.99M5.63M10.92M17.1M
Operating Expenses14.65M17.62M20.97M26.99M53.33M
Depreciation & Amortization87.47K147.89K117.1K171.6K331.89K
EBITDA(17.22M)(17.86M)(20.78M)(24.95M)(53.33M)
EBITDA Margin—————
Operating Income(14.65M)(17.62M)(20.97M)(26.99M)(53.66M)
Operating Margin—————
Interest Income51.55K431.8K649.75K1.16M1.41M
Interest Expense1.02M982.86K881.05K603.17K0
Other Income / Expenses(3.68M)(1.37M)(814.93K)1.26M(212.94K)
Income Before Tax(18.33M)(18.99M)(21.78M)(25.73M)(53.87M)
Pre-Tax Margin—————
Income Tax Expense0027.42K1.8K26.65K
Net Income(18.03M)(18.49M)(21.25M)(25.49M)(53.86M)
Net Margin—————
EPS (Basic)(1.63)(0.96)(0.88)(0.76)(1.05)
EPS (Diluted)(1.63)(0.96)(0.88)(0.76)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.